Back to School: How biopharma can reboot drug development. Access exclusive analysis here

0929 ECP OriCiro
BioCentury & Getty Images

Emerging Company Profile

OriCiro: replacing conventional bacterial cloning

OriCiro’s method includes cell-free synthesis and amplification of large circular DNA

OriCiro aims to replace conventional bacterial cloning with a cell-free system for synthesis and amplification of large circular DNA.

Oct 3, 2020 | 3:18 AM GMT

OriCiro aims to provide plasmid DNA manufacturing to pharmas using a

Read the full 583 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers